CN111269313B - A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof - Google Patents
A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof Download PDFInfo
- Publication number
- CN111269313B CN111269313B CN202010154392.2A CN202010154392A CN111269313B CN 111269313 B CN111269313 B CN 111269313B CN 202010154392 A CN202010154392 A CN 202010154392A CN 111269313 B CN111269313 B CN 111269313B
- Authority
- CN
- China
- Prior art keywords
- protein
- ser
- monoclonal antibody
- ala
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a monoclonal antibody for detecting novel coronavirus and application of a preparation kit thereof. The N protein is an important marker protein of the coronavirus, and the detection of the N protein can realize the detection of the coronavirus. The anti-N protein monoclonal antibody obtained by the invention has the characteristics of high specificity and mass production, and the titer of the obtained antibody is high. The anti-N protein monoclonal antibody obtained by the invention can be specifically combined with N protein, can be used for immunological detection of cells, has wide market prospect and has important clinical significance.
Description
Technical Field
The invention belongs to the field of biological detection, and particularly relates to a monoclonal antibody for detecting a novel coronavirus and application of a preparation kit of the monoclonal antibody.
Background
After people are infected with coronavirus, the common signs of the person are respiratory symptoms, fever, cough, shortness of breath, dyspnea and the like. In more severe cases, the infection can lead to pneumonia, severe acute respiratory syndrome, renal failure, and even death. Although no specific treatment method exists for diseases caused by the novel coronavirus, the cure rate of patients with mild diseases or asymptomatic diseases can be greatly improved and the treatment time can be shortened by treating the patients with mild diseases or asymptomatic diseases. Therefore, the detection or identification of the patient becomes particularly important.
Rapid and accurate diagnosis of infectious diseases is a key factor in controlling outbreaks of diseases. With the increasing number of people infected with the novel coronavirus (2019-nCoV), many in vitro diagnostic companies have introduced novel coronavirus detection kits, and many biological companies have competed by providing detection reagents.
There is room for improvement in accuracy and sensitivity of nucleic acid detection. Therefore, antibody detection kits are becoming more important. The novel coronavirus gene encodes a plurality of structural proteins, such as N protein, E protein, S protein and the like, the proteins comprise a plurality of antigen epitopes, and the existence of the antigen can be detected through the antibody by utilizing the principle that the antigen is specifically combined with the antibody, so that the fact that the sample contains the novel coronavirus is directly proved. The antigen of the novel coronavirus can be used as immunogen, plasma cells are stimulated to generate specific antibody after the virus infects human body, and the existence of the antibody can be detected through the antigen by utilizing the principle of the specific combination of the antigen and the antibody, thereby indirectly proving that the human body is infected with the novel coronavirus. Suitable sample types for antibody detection reagents are typically blood, including serum, plasma, and whole blood.
The detected antibodies are mainly divided into IgM and IgG. There is currently no systematic study of the production and duration of these two classes of antibodies to the novel coronaviruses. Usually, IgM antibodies are produced early, rapidly produced upon infection, maintained for a short time, and disappeared rapidly, and detection of positivity in blood can be used as an indicator of early infection. The IgG antibody is produced late, maintained for a long time, disappeared slowly, and the positive detection in blood can be used as the index of infection and past infection.
Therefore, the development of antibody detection kits becomes particularly important.
Disclosure of Invention
The invention provides a coronavirus N protein with better immunogenicity, wherein the nucleotide sequence of the coronavirus N protein is shown as SEQ ID NO: 1, and the following components:
the amino acid sequence is shown in SEQ ID NO. 2:
the invention also provides a method for expressing the N protein, which comprises cloning the N protein gene, expressing in Escherichia coli, and purifying to obtain the corresponding N protein.
The invention also provides a method for preparing the monoclonal antibody with the specificity of the N protein, which comprises the steps of immunizing a mouse by taking the N protein as an immunogen, and preparing and obtaining the monoclonal antibody.
The invention firstly uses N protein to immunize a mouse, then spleen lymphocytes of the successfully immunized mouse are fused with myeloma cells, and a hybridoma cell strain with specificity secreting the anti-N protein monoclonal antibody is obtained by screening positive clones, is used for mass production of the anti-N protein monoclonal antibody, and is prepared to obtain the high-purity anti-N protein monoclonal antibody in a protein purification mode.
The invention particularly relates to a monoclonal antibody, wherein the heavy chain variable region amino acid sequence of the monoclonal antibody is SEQ.ID.NO.9:
QIQLQQSGASLVRPGALVKLSCKASDSHYYSQSLHWVKQRPVQGLEWIGDIGSADNSTKYAPPFLGKAQITADTSSNTAYLQLSSLTSEDTAVYYCIRYASSGWGWGQGTTLTVSS。
the amino acid sequence of the light chain variable region sequence is SEQ.ID.NO.10:
DIVITQSPALMADSPGEKVTITCDYSEEISMSYLAWYQQSSGISPKPWIYTTAGLAPGVPARFSGSGSGTSYSLTITSAEAEDAATYYCSSASSLPCRFGAGTKLELK。
the invention also provides an application of the anti-N protein monoclonal antibody, and the application is to prepare an ELISA kit.
The invention relates to an application of an anti-N protein monoclonal antibody, in particular to an application of the anti-N protein monoclonal antibody in immunological detection, in particular to the detection of N protein, thereby identifying whether coronavirus exists or not.
The invention has the beneficial effects that:
the N protein is an important marker protein of the coronavirus, and the detection of the N protein can realize the detection of the coronavirus. The anti-N protein monoclonal antibody obtained by the invention has the characteristics of high specificity and mass production, and the titer of the obtained antibody is high. The anti-N protein monoclonal antibody obtained by the invention can be specifically combined with N protein, can be used for immunological detection of cells, has wide market prospect and has important clinical significance.
Drawings
FIG. 1 is a comparison between before and after the optimization of the N protein gene, wherein 1A is a diagram before the optimization and 1B is a diagram after the optimization.
FIG. 2 is a graph of antibody titer results; the dark column is antibody and the light column is control.
FIG. 3 shows the result of Western blot experiment of N protein with mAb monoclonal antibody. 1 is a self-made marker, 2-4 are lysates of blank host bacteria BL21(DE3), blank host bacteria BL21(DE3), blank plasmid lysates, and 5 is N protein.
Detailed Description
Embodiments of the present application will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present application and should not be construed as limiting the scope of the present application. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by manufacturers, and are all conventional products available on the market.
Example 1 epitope optimization of N protein
According to the whole genome sequence already disclosed by 2019-nCoV, an optimized N protein epitope amino acid sequence is designed aiming at the N protein amino acid sequence peptide. The sequence is analyzed by 5 amino acid sequences of different strains such as Chinese strain, Italian strain and the like through Clustal W (Version1.81) software multi-sequence alignment, and the immunogenicity, the hydrophilicity, the surface possibility and the related secondary structure of the strain are analyzed according to DNAstar. A three-dimensional structure of the protein is constructed through Modeller homologous modeling, the surface possibility of the immunogen polypeptide is further analyzed, an antibody binding epitope peptide is simulated through MOE software, interacting amino acids are analyzed, an N protein sequence with better immunogenicity is obtained through screening, and in comparison between a graph shown in figure 1A and a graph shown in figure 1B, the optimized codon sequence shown in figure 1B enables the GC content in the N protein sequence to be 50.40, so that the N protein sequence is more suitable for protein expression.
The nucleotide sequence is shown as SEQ ID NO: 1, and the following components:
the amino acid sequence is shown in SEQ ID NO. 2:
EXAMPLE 2 expression of N protein
Designing specific primers according to the optimized N protein nucleotide sequence, and respectively adding protective bases and restriction endonucleases into the 5' ends of the primers, wherein the primer sequences are as follows:
F:5'-CGCGGATCCATGAAAGACCTGTCTCCGCG-3'(SEQ.ID.NO.3)：
R:5'-CCGGAATTCGTCGTCCAGTTTGATAGCAC-3'(SEQ.ID.NO.4)：
the optimized N protein gene synthesized by the whole gene is used as a template (synthesized in Shanghai), and PCR amplification is carried out by using the specific primer.
The PCR reaction program is: pre-denaturation at 94 ℃ for 2 min; denaturation at 94 ℃ for 10sec, annealing at 55 ℃ for 35sec, extension at 67 ℃ for 1min for 10s, 35 cycles; extension at 68 deg.C for 7min, and storage at 4 deg.C.
And (3) PCR reaction system: 2 XPCR Buffer 12.5. mu.L, 2mM dNTPs 5. mu.L,
10mM R Primer 0.75μL，10mM F Primer 0.75μL，N DNA 1μL，dH2O 5μL。
the amplified product was double digested with restriction enzymes BamHI and EcoRI and vector pColdI, respectively, in the form of 9.5. mu.L PCR product or vector, 0.5. mu.L BamHI, 0.5. mu.L EcoRI, 8.5. mu.L dH2And O. And reacting for 1h at 37 ℃. The digested product was subjected to 1% agarose gel electrophoresis, and recovered and purified by using an agarose gel DNA purification kit from Takara.
The enzyme digestion product N gene and pColdI are connected by adopting a Ligation Kit DNA Ligation Kit (Mighty Mix) of Takara company, the mol ratio of the prepared recombinant prokaryotic expression vector pCold-N.N and pColdI is about 3: 1.16 ℃, the connection is carried out for 1 hour, the Ligation product is transformed into an escherichia coli competent cell DH5 alpha in a heat shock transformation mode, overnight culture is carried out at 37 ℃, and a positive plasmid with positive colony PCR and enzyme digestion identification is selected for sequencing identification, and the sequence is consistent with SEQ ID NO 1 after identification.
The correctly sequenced plasmid pCold-N was transformed into an expression form of E.coli competent cells BL21 by means of heat shock transformation (DE 3). And (5) determining positive bacteria by colony PCR, namely expression bacteria containing recombinant expression plasmid pCold-NS 3. Inoculating an expression bacterium containing a recombinant expression plasmid pCold-NS3 into an autoinduction expression medium for inducing expression, wherein the autoinduction medium is Overnight ExpressTM Instant LB Media, and the step of inducing expression comprises the following steps: a small amount of the bacterial liquid was inoculated into 3mL of LB liquid medium containing Amp and cultured overnight at 37 ℃. Adding the overnight cultured bacterial liquid into an Amp-containing self-induction culture medium according to the proportion of 1:100, and inducing for 22h at the temperature of 17 ℃. The expression product is purified by recombinant protein through a QIAGEN His-tag protein purification kit, and then SDS-PAGE analysis is carried out, and the result shows that the protein accounts for more than 51 percent of the total expression protein amount by the method provided by the invention, and the expression amount is extremely obvious. The concentration of the protein after the preparation and purification is 0.5mg/L for standby.
EXAMPLE 3 preparation of monoclonal antibodies
Balb-c mice were 15, female, 8 weeks, and had a body mass (20. + -.2 g) provided by the laboratory animal center, Yangzhou university. The groups were randomized into 3 groups of 5 individuals. The N protein obtained in example 2 is used as immunogen, after fully emulsifying with equivalent Freund's complete adjuvant, the antigen is injected into mice at multiple points at subcutaneous sites according to 70 ug/mouse, 2 weeks later, 2 nd immunization is carried out with Freund's incomplete adjuvant emulsion antigen, 3 times of immunization are followed by detection of ELISA titer > 1: after 1 ten thousand, 50g of antigen is used for abdominal cavity impact immunization, and fusion is carried out after 3-4 days.
Taking a spleen of a mouse aseptically, preparing splenocytes, and fusing the splenocytes with myeloma SP2/O cells in a logarithmic growth phase by using PEG4000 with the volume fraction of 50 percent; suspending the fused cells by using an HAT culture medium, culturing in a 96-well plate in a CO2 culture box with the temperature of 37 ℃ and the volume fraction of 5%, replacing the 1/2HAT culture medium by using HT after 5 days, replacing the HT culture medium by using the HT culture medium after 7-10 days, regularly observing, screening positive clones by adopting an indirect ELISA method 2 days after 2-3 times of liquid replacement, and continuing subcloning for 2 times by adopting a limiting dilution method. An ELISA plate is coated by N protein, and after 3 times of subcloning, a positive monoclonal cell line with good morphology, vigorous growth and stable reaction is obtained and named as N-32 after ELISA result screening. The ascites is purified by salting out with saturated ammonium sulfate. And (4) carrying out protein quantification by using an ultraviolet spectrophotometer. Purification gave mAb at a concentration of 2.0 g/L.
Example 4 identification of mAbs
(1) Subclass identification: goat anti-mouse IgG, IgG1, IgG2a, IgG2b, IgG3 and IgM were subjected to immunodiffusion with hybridoma cell culture supernatants concentrated 10-fold, and formation of a precipitation line was observed. The mAb is detected to be of IgG2a subtype by immunodiffusion.
(2) Determination of potency and relative affinity:
and (3) measuring the titer:
diluting the N protein to 1 mu g/mL by using a carbonate buffer solution with the pH value of 9.6 and the concentration of 0.05mol/L, coating an enzyme label plate, coating 100 mu L/hole and standing overnight at the temperature of 4 ℃; the monoclonal antibodies were mixed at a ratio of 1:10 with a sample diluent (phosphate buffer containing 0.5% bovine serum albumin)3、1:104、1：105、1：106、1：107、1：108、1：109、1：1010Diluting, 100 mu L/hole, and incubating for 1h at 37 ℃; taking out the ELISA plate, washing for 3 times by TBS-T, patting the ELISA plate dry, adding 100 μ L of HRP-labeled goat anti-mouse secondary antibody diluted by 1:5000 into each hole, and incubating for 30min at 37 ℃; after TBS-T washing for 5 times, adding 100 μ L of TMB substrate display solution into each well, developing in dark at 37 deg.C for 10-15min, adding 50 μ L of stop solution to stop reaction, reading light absorption value at 450nm wavelength of microplate reader, and the result is shown in FIG. 2, where the titer of the purified monoclonal antibody reaches 8.6 × 10-9。
And (3) affinity identification: the different concentrations of the test mAbs are plotted on the abscissa and the corresponding A values are plotted on the ordinate to determine a curve, the A value of the upper plateau of the curve is 100%, and the concentration of the mAb at the point where the A value is 50% represents the relative affinity of the mAb. The results showed that the relative affinity of the mAb determined by indirect ELISA was 1.835X 10-10mol/L, shows better affinity.
(3) And (3) specific identification: the binding activity of the mAb to the N protein was determined by Western blot: carrying out SDS-PAGE on the purified N protein, transferring the gel protein to a nitrocellulose membrane in a charged manner, sequentially reacting with mAb and HRP-goat anti-mouse IgG, then developing the gel with DAB, carrying out cross-reactivity detection on the mAb and corresponding N protein antigens of HBV, HEV and HCV antigens, and adopting indirect ELISA.
Western blot identification as shown in FIG. 3 indicates that mAb can recognize a band with an Mr of about 20-30KD, indicating binding to the N protein of interest; no cross reaction with the lysate of the host bacterium BL21(DE3) or the empty plasmid lysate was observed. The mAb has no binding reaction with the corresponding N protein antigens of HBV, HEV and HCV antigens by an indirect ELISA method.
Example 5 identification of mAb sequences
The screened hybridoma cells of example 3 were collected, total RNA of the hybridoma cells was extracted using Trizol of Thermo, and mRNA was reverse-transcribed into cDNA according to the protocol of HiScript Q RT Supermix for qPCR (+ gDNA wiper) of Nanjing Novonza, and frozen at-20 ℃ for use. The reverse transcription system consisted of 5. mu.L of RNA (2500ng), 10. mu.L of 4 XgDNA, 10. mu.L of 5 Xsupermix II, and ddH2O to make up to 50. mu.L, with a total reaction volume of 50. mu.L.
Using cDNA as a template, searching the gene sequences of a murine heavy chain FR1 region and a hinge region through an NCBI database, designing a heavy chain PCR primer according to the sequences, wherein the upstream sequence is (SEQ. ID. NO. 5):
GCGCTCGAGCAGKTCCAGCTGAAGCAGTC, the downstream sequence is (SEQ. ID. NO. 6):
GCGACTAGTGCATTTGCATGGAGGACAG, respectively; similarly, the murine FR1 region of light chain and the gene sequence of constant region (NC000072.6) were searched by NCBI database, and light chain PCR primers were designed, with the upstream sequence (seq. id No. 7):
GCGGAGCTCGATRTTGTGATGACCCARAC, the downstream sequence is (SEQ. ID. NO. 8):
GCGTCTAGACTCATTCCTGTTGAAGCTCT, the light and heavy chain fragments of the antibody were obtained by PCR, respectively. The PCR was carried out according to the protocol of Phanta Max Super-Fidelity DNA Polymerase of Nanjing Nodezak company, and the PCR reaction system was: 25 μ L of 2 XPPhanta, 1 μ L dNTP, 4 μ L of 10 μ M primer pair, 4 μ L hybridoma cDNA, 1 μ L DNA polymerase, 15 μ L dd H2O, and a total reaction volume of 50 μ L. The amplification conditions were: pre-denaturation at 94 deg.C for 3 min; denaturation at 94 ℃ for 30 s; annealing at 64 ℃ for 30 s; extension was 72 ℃ for 5 min. And (3) performing Gel recovery on the PCR product according to the instruction of an OMEGA Gel Extraction Kit of the OMEGA company, and performing sequencing analysis to obtain the hybridoma cell with the amino acid sequence of the heavy chain variable region of SEQ.ID.NO.7 and the amino acid sequence of the light chain variable region of SEQ.ID.NO. 8.
The heavy chain variable region amino acid sequence is SEQ.ID.NO.9:
QIQLQQSGASLVRPGALVKLSCKASDSHYYSQSLHWVKQRPVQGLEWIGDIGSADNSTKYAPPFLGKAQITADTSSNTAYLQLSSLTSEDTAVYYCIRYASSGWGWGQGTTLTVSS
the amino acid sequence of the light chain variable region sequence is SEQ.ID.NO.10:
DIVITQSPALMADSPGEKVTITCDYSEEISMSYLAWYQQSSGISPKPWIYTTAGLAPGVPARFSGSGSGTSYSLTITSAEAEDAATYYCSSASSLPCRFGAGTKLELK。
it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of components set forth in the following description and/or illustrated in the drawings. The invention is capable of embodiments in addition to those described and of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.
As such, those skilled in the art will appreciate that the conception, upon which this disclosure is based, may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.
Sequence listing
<110> Beijing Yuehao science and technology development Co., Ltd
<120> monoclonal antibody for detecting novel coronavirus and application of preparation kit thereof
<160> 10
<170> SIPOSequenceListing 1.0
<210> 1
<211> 723
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
atgaaagacc tgtctccgcg ttggtacttc tactacctgg gtaccggtcc ggaagctggt 60
ctgccgtacg gtgctaacaa agacggtatc atctgggttg ctaccgaagg tgctctgaac 120
accccgaaag accacatcgg tacccgtaac ccggctaaca acgctgctat cgttctgcag 180
ctgccgcagg gtaccaccct gccgaaaggt ttctacgctg aaggttctcg tggtggttct 240
caggcttctt ctcgttcttc ttctcgttct cgtaactctt ctcgtaactc taccccgggt 300
tcttctcgtg gtacctctcc ggctcgtatg gctggtaacg gtggtgacgc tgctctggct 360
ctgctgctgc tggaccgtct gaaccagctg gaatctaaaa tgtctggtaa aggtcagcag 420
cagcagggtc agaccgttac caaaaaatct gctgctgaag cttctaaaaa accgcgtcag 480
aaacgtaccg ctaccaaagc ttacaacgtt acccaggctt tcggtcgtcg tggtccggaa 540
cagacccagg gtaacttcgg tgaccaggaa ctgatccgtc agggtaccga ctacaaacac 600
tggccgcaga tcgctcagtt cgctccgtct gcttctgctt tcttcggtat gtctcgtatc 660
ggtatggaag ttaccccgtc tggtacctgg ctgacctaca ccggtgctat caaactggac 720
gac 723
<210> 2
<211> 241
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 2
Met Lys Asp Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr Leu Gly Thr Gly
1 5 10 15
Pro Glu Ala Gly Leu Pro Tyr Gly Ala Asn Lys Asp Gly Ile Ile Trp
20 25 30
Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys Asp His Ile Gly Thr
35 40 45
Arg Asn Pro Ala Asn Asn Ala Ala Ile Val Leu Gln Leu Pro Gln Gly
50 55 60
Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly Ser Arg Gly Gly Ser
65 70 75 80
Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg Asn Ser Ser Arg Asn
85 90 95
Ser Thr Pro Gly Ser Ser Arg Gly Thr Ser Pro Ala Arg Met Ala Gly
100 105 110
Asn Gly Gly Asp Ala Ala Leu Ala Leu Leu Leu Leu Asp Arg Leu Asn
115 120 125
Gln Leu Glu Ser Lys Met Ser Gly Lys Gly Gln Gln Gln Gln Gly Gln
130 135 140
Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser Lys Lys Pro Arg Gln
145 150 155 160
Lys Arg Thr Ala Thr Lys Ala Tyr Asn Val Thr Gln Ala Phe Gly Arg
165 170 175
Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly Asp Gln Glu Leu Ile
180 185 190
Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile Ala Gln Phe Ala
195 200 205
Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile Gly Met Glu Val
210 215 220
Thr Pro Ser Gly Thr Trp Leu Thr Tyr Thr Gly Ala Ile Lys Leu Asp
225 230 235 240
Asp
<210> 3
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 3
cgcggatcca tgaaagacct gtctccgcg 29
<210> 4
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 4
ccggaattcg tcgtccagtt tgatagcac 29
<210> 5
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 5
gcgctcgagc agktccagct gaagcagtc 29
<210> 6
<211> 28
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 6
gcgactagtg catttgcatg gaggacag 28
<210> 7
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 7
gcggagctcg atrttgtgat gacccarac 29
<210> 8
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 8
gcgtctagac tcattcctgt tgaagctct 29
<210> 9
<211> 116
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 9
Gln Ile Gln Leu Gln Gln Ser Gly Ala Ser Leu Val Arg Pro Gly Ala
1 5 10 15
Leu Val Lys Leu Ser Cys Lys Ala Ser Asp Ser His Tyr Tyr Ser Gln
20 25 30
Ser Leu His Trp Val Lys Gln Arg Pro Val Gln Gly Leu Glu Trp Ile
35 40 45
Gly Asp Ile Gly Ser Ala Asp Asn Ser Thr Lys Tyr Ala Pro Pro Phe
50 55 60
Leu Gly Lys Ala Gln Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80
Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ile Arg Tyr Ala Ser Ser Gly Trp Gly Trp Gly Gln Gly Thr Thr Leu
100 105 110
Thr Val Ser Ser
115
<210> 10
<211> 108
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 10
Asp Ile Val Ile Thr Gln Ser Pro Ala Leu Met Ala Asp Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Asp Tyr Ser Glu Glu Ile Ser Met Ser
20 25 30
Tyr Leu Ala Trp Tyr Gln Gln Ser Ser Gly Ile Ser Pro Lys Pro Trp
35 40 45
Ile Tyr Thr Thr Ala Gly Leu Ala Pro Gly Val Pro Ala Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Ala Glu
65 70 75 80
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Ser Ser Ala Ser Ser Leu Pro
85 90 95
Cys Arg Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010154392.2A CN111269313B (en) | 2020-03-07 | 2020-03-07 | A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010154392.2A CN111269313B (en) | 2020-03-07 | 2020-03-07 | A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111269313A CN111269313A (en) | 2020-06-12 |
| CN111269313B true CN111269313B (en) | 2021-05-28 |
Family
ID=70995546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010154392.2A Active CN111269313B (en) | 2020-03-07 | 2020-03-07 | A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111269313B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113823415A (en) * | 2020-06-18 | 2021-12-21 | 香港奇岱松科技有限公司 | Systems and applications to improve the health safety of people in the environment against infectious diseases |
| CN112521494B (en) * | 2020-06-19 | 2021-06-25 | 武汉生物制品研究所有限责任公司 | Monoclonal antibody 2B11 for resisting SARS-CoV-2 |
| CN111751527A (en) * | 2020-06-29 | 2020-10-09 | 丹娜(天津)生物科技股份有限公司 | Novel coronavirus IgG and IgM antibody detection kit and preparation method and application thereof |
| CN111647079B (en) * | 2020-07-03 | 2021-11-16 | 北部湾大学 | Neutralizing antibody for resisting novel coronavirus N protein |
| CN113943367B (en) * | 2020-07-15 | 2023-08-25 | 安诺柏德生物医药科技(苏州)有限公司 | Single domain antibodies against novel coronaviruses, kits and medicaments |
| WO2022029494A1 (en) * | 2020-08-04 | 2022-02-10 | Abbott Rapid Diagnostics International Unlimited Company | Assays for detecting sars-cov-2 |
| CN114058593A (en) * | 2020-08-06 | 2022-02-18 | 中国人民解放军陆军军医大学 | Monoclonal antibody of N antigen of SARS-CoV-2, detection method and use thereof |
| CN115925903B (en) * | 2020-08-19 | 2025-01-28 | 重庆医科大学 | Novel coronavirus RBD-specific monoclonal antibodies and their applications |
| WO2022069232A1 (en) * | 2020-10-02 | 2022-04-07 | Institut Pasteur | Single domain antibodies against the nucleoprotein of sars-cov-2 |
| CN116829951A (en) * | 2020-11-02 | 2023-09-29 | 豪夫迈·罗氏有限公司 | SARS-CoV-2 nucleocapsid antibodies |
| CN116635411A (en) * | 2020-11-17 | 2023-08-22 | 富士胶片株式会社 | The detection kit of SARS-CoV-2 and the detection method of SARS-CoV-2 |
| CN113150133B (en) * | 2021-03-15 | 2022-10-11 | 安源医药科技（上海）有限公司 | Monoclonal antibodies against SARS-CoV-2 or antigen binding fragments thereof |
| CN113150136B (en) * | 2021-04-30 | 2022-04-01 | 杭州贤至生物科技有限公司 | Preparation of novel coronavirus N protein monoclonal antibody |
| CN115304670B (en) * | 2021-05-07 | 2024-07-30 | 华南农业大学 | Murine monoclonal antibody of feline coronavirus nucleocapsid protein, encoding gene and application thereof |
| CN113754761A (en) * | 2021-09-08 | 2021-12-07 | 苏州博特龙免疫技术有限公司 | Monoclonal antibody for detecting new coronavirus |
| CN116554315B (en) * | 2021-11-08 | 2024-09-24 | 东莞市朋志生物科技有限公司 | Antibodies against novel coronaviruses, reagents and kits for detecting novel coronaviruses |
| CN113912710B (en) * | 2021-11-17 | 2023-05-26 | 杭州旭科生物技术有限公司 | Monoclonal antibody for resisting novel coronavirus N protein and application thereof |
| CN116003585A (en) * | 2022-12-27 | 2023-04-25 | 北京乐普诊断科技股份有限公司 | Novel coronavirus N protein monoclonal antibody, preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109666070B (en) * | 2017-10-13 | 2021-02-19 | 清华大学 | Monoclonal antibody MERS-4V2 and coding gene and application thereof |
-
2020
- 2020-03-07 CN CN202010154392.2A patent/CN111269313B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111269313A (en) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111269313B (en) | A kind of monoclonal antibody for detecting novel coronavirus and use of preparation kit thereof | |
| CN113912710B (en) | Monoclonal antibody for resisting novel coronavirus N protein and application thereof | |
| CN111153991A (en) | Human SARS-CoV-2 monoclonal antibody and its preparation method and use | |
| CN112552396B (en) | anti-African swine fever virus p54 protein monoclonal antibody, preparation method and application | |
| CN113151187B (en) | Monoclonal antibody hybridoma cell of African swine fever virus and application thereof | |
| CN111239394B (en) | A kit for rapid detection of novel coronavirus antibodies based on mixed antigens | |
| CN113354717B (en) | A novel coronavirus SARS-CoV-2 broad-spectrum polypeptide antigen and its specific neutralizing antibody and application | |
| CN118420750B (en) | Monoclonal antibody 8D7 or its antibody fragment against monkeypox virus A35R protein | |
| CN112940087B (en) | A SARS-CoV and SARS-CoV-2 common epitope peptide and its application | |
| CN113150138B (en) | KPC-2 monoclonal antibody, and preparation method and application thereof | |
| CN114057870B (en) | Labeled antibody for detecting novel coronavirus Delta mutant strain and application thereof | |
| CN112920278B (en) | Novel coronavirus specific fusion protein antigen and preparation method and application thereof | |
| CN110128535A (en) | A kind of AMH monoclonal antibody and its preparation and application | |
| CN116836270A (en) | A monoclonal antibody against bluetongue virus VP7 protein and its preparation method and use | |
| CN114276445A (en) | Rotavirus recombinant protein specific antibody, plasmid vector and method | |
| CN106632619A (en) | Influenza A virus recombinant protein and preparation of monoclonal antibody thereof | |
| CN114555642A (en) | Method for improving affinity of antibody for antigen and use thereof | |
| CN113563461B (en) | A competitive monoclonal antibody, kit and application based on African swine fever virus CD2v protein | |
| CN115028713A (en) | An antibody against coronavirus N protein and its application | |
| CN112500494B (en) | Antigen for detecting novel coronavirus and preparation method thereof | |
| CN109734791A (en) | People NF186 antigen, people's NF186 antibody assay kit and the preparation method and application thereof | |
| CN110016466B (en) | Monoclonal antibody for specifically detecting bluetongue virus, hybridoma cell strain and application thereof | |
| CN114349855B (en) | Novel coronavirus Delta mutant strain-specific antibody and its application | |
| CN118496349B (en) | Monoclonal antibody 2D7 or its antibody fragment against monkeypox virus A35R protein | |
| CN110702913A (en) | A kind of monoclonal antibody composition for quantitative detection of C. beriberi phase I strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210511 Address after: 102600 room 209, 2nd floor, building 10, No.26 courtyard, Yongwang West Road, Daxing biomedical industrial base, Zhongguancun Science and Technology Park, Daxing District, Beijing Applicant after: Beijing Shunjing Biomedical Technology Co., Ltd Address before: 4315, 4th Floor, Building No. 7, Fengxianzhong Road, Haidian District, Beijing, 100000 Applicant before: BEIJING YUEHAO TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |